172 related articles for article (PubMed ID: 18370442)
1. Temsirolimus: in advanced renal cell carcinoma.
Simpson D; Curran MP
Drugs; 2008; 68(5):631-8. PubMed ID: 18370442
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus.
Stock C; Zaccagnini M; Schulze M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2010; 184():189-97. PubMed ID: 20072839
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus.
Schulze M; Stock C; Zaccagnini M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2014; 201():393-403. PubMed ID: 24756806
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
Sun Y; Rha S; Lee SH; Guo J; Ueda T; Qin S; Naito S; Cincotta M; Tokushige K; Akaza H
Jpn J Clin Oncol; 2012 Sep; 42(9):836-44. PubMed ID: 22844126
[TBL] [Abstract][Full Text] [Related]
6. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus: new drug. Metastatic kidney cancer: more assessment needed.
Prescrire Int; 2008 Dec; 17(98):223-5. PubMed ID: 19415885
[TBL] [Abstract][Full Text] [Related]
9. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
Kwitkowski VE; Prowell TM; Ibrahim A; Farrell AT; Justice R; Mitchell SS; Sridhara R; Pazdur R
Oncologist; 2010; 15(4):428-35. PubMed ID: 20332142
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
11. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.
Zbrozek AS; Hudes G; Levy D; Strahs A; Berkenblit A; DeMarinis R; Parasuraman S
Pharmacoeconomics; 2010; 28(7):577-84. PubMed ID: 20550223
[TBL] [Abstract][Full Text] [Related]
12. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Maroto JP; Hudes G; Dutcher JP; Logan TF; White CS; Krygowski M; Cincotta M; Shapiro M; Duran I; Berkenblit A
J Clin Oncol; 2011 May; 29(13):1750-6. PubMed ID: 21444868
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
15. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
Dutcher JP; de Souza P; McDermott D; Figlin RA; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Hudes G
Med Oncol; 2009; 26(2):202-9. PubMed ID: 19229667
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
[TBL] [Abstract][Full Text] [Related]
17. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
Bellmunt J; Szczylik C; Feingold J; Strahs A; Berkenblit A
Ann Oncol; 2008 Aug; 19(8):1387-1392. PubMed ID: 18385198
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
20. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
Bhatia S; Thompson JA
Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
